| Literature DB >> 31147265 |
Daniel Halstuch1, Yaara Ber1, David Margel2.
Abstract
Male carriers of BRCA mutations are at higher risk of developing prostate cancer. Many issues are still unanswered and are currently being studied, including differences between BRCA1 and BRCA2, screening and specific protocols, the role of active surveillance, and the choice of definitive treatment.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31147265 DOI： 10.1016/j.euf.2019.05.009
Source DB: PubMed Journal: Eur Urol Focus ISSN： 2405-4569